Summary
Johnson & Johnson reported solid performance for the second quarter of 2024, demonstrating revenue growth driven by strong performance in its Innovative Medicine and MedTech segments. Total sales increased by 4.3% year-over-year to $22.4 billion, with operational growth of 6.6%, partially offset by currency headwinds. The Innovative Medicine segment saw a 5.5% increase in sales, propelled by robust growth in Oncology and Pulmonary Hypertension, despite a decline in COVID-19 vaccine revenue and ongoing biosimilar competition for certain products. The MedTech segment also delivered growth, up 2.2%, boosted by acquisitions and strong performance in Cardiovascular and Orthopaedics. Financially, the company maintained healthy profitability, although earnings before taxes saw a slight decrease due to significant charges related to acquisitions and ongoing litigation settlements, particularly concerning talc matters. The company continues to navigate substantial legal proceedings, notably the talc and opioid litigations, which have resulted in significant accruals. Despite these challenges, Johnson & Johnson's liquidity remains strong, with substantial cash and cash equivalents, and effective management of its debt obligations. The company's strategic acquisitions, including Shockwave Medical, are expected to contribute to future growth, showcasing a continued focus on expanding its portfolio in key areas.
Financial Highlights
52 data points| Revenue | $22.45B |
| Cost of Revenue | $6.87B |
| Gross Profit | $15.58B |
| SG&A Expenses | $5.68B |
| Operating Income | $7.94B |
| Net Income | $4.69B |
| EPS (Basic) | $1.95 |
| EPS (Diluted) | $1.93 |
| Shares Outstanding (Basic) | 2.41B |
| Shares Outstanding (Diluted) | 2.42B |
Key Highlights
- 1Worldwide sales increased by 4.3% to $22.4 billion for the second quarter of 2024, driven by operational growth of 6.6%.
- 2Innovative Medicine segment sales grew 5.5% to $14.5 billion, with notable operational growth in Oncology and Pulmonary Hypertension.
- 3MedTech segment sales increased by 2.2% to $8.0 billion, supported by the acquisition of Shockwave Medical and growth in Cardiovascular and Orthopaedics.
- 4The company incurred significant charges related to acquisitions, including the Shockwave Medical acquisition, and ongoing litigation settlements, impacting profitability.
- 5Consolidated earnings before provision for taxes decreased to $5.7 billion from $6.3 billion in the prior year's quarter, partly due to substantial talc litigation charges.
- 6The company maintained a strong liquidity position with $24.9 billion in cash and cash equivalents as of June 30, 2024.
- 7Strategic acquisitions, such as Shockwave Medical, were completed to bolster the MedTech portfolio, with further investments in R&D for future growth.